Pharmaceutical composition for preventing or treating sepsis

N-dodecyl-4-hydroxybenzamide-based pharmaceuticals inhibit cytokine storm and immune cell activity, addressing the inadequacies of current sepsis treatments by effectively reducing sepsis severity and onset, applicable in human and veterinary medicine and as a food additive.

KR1020260162018APending Publication Date: 2026-11-10INJE UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020250058135
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current treatments for sepsis, particularly those targeting cytokine storms, are inadequate and have high mortality rates, with no fundamental cure identified, and existing drugs like Drotrecogin alpha have shown limited efficacy, necessitating the development of safer and more effective therapeutic agents.

Method used

A pharmaceutical composition containing N-dodecyl-4-hydroxybenzamide, its pharmaceutically acceptable salts, hydrates, or solvates, is developed to inhibit cytokine storm and immune cell activity, thereby preventing or treating sepsis by suppressing the expression of TNF-α, IL-1β, IL-6, IFN-γ, and iNOS.

Benefits of technology

The composition effectively suppresses cytokine storm and septic shock, reducing the severity and onset of sepsis, with potential applications in human and veterinary medicine, and as a food additive to enhance immune function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00009_ABST
    Figure PAT00009_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of sepsis. Since the composition of the present invention has an excellent cytokine storm suppression effect in sepsis and septic shock, it can be usefully used as an active ingredient in a composition for the prevention or treatment of such conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of sepsis. Background Technology

[0002] A cytokine storm refers to a phenomenon in which the immune system within the human body becomes overactive in response to invading viruses, attacking even normal cells. In other words, it is a reaction in which the DNA of normal cells is altered due to the excessive secretion of cytokines, which are immune substances, leading to symptoms of secondary infection. Cytokine storms were identified as a major cause of high mortality rates during past outbreaks of the Spanish flu and avian flu.

[0003] Generally, when the immune system fights against infections by pathogens such as bacteria, chemokines—a type of cytokine produced at the site of infection—attract immune cells, such as neutrophils and macrophages, to the infection site. Large quantities of inflammatory cytokines are secreted by the cells residing at the infection site and the additional immune cells that gather there; these inflammatory cytokines themselves stimulate immune cells to produce even more inflammatory cytokines. This phenomenon, in which inflammatory cytokines increase rapidly within a host infected with a pathogen, is called a "cytokine storm" because it resembles a rising storm.

[0004] The occurrence and exacerbation of such cytokine storms are directly linked to sepsis or septic shock. Since a cytokine storm is the primary phenomenon occurring within the body when sepsis develops, attempts are being made to regulate inflammatory cytokines to treat the condition.

[0005] Sepsis is caused by the body's abnormal defense mechanism against infected microorganisms. It is associated with the activation of macrophages and the subsequent excessive production of inflammation-related factors, leading to a severe systemic inflammatory response. Sepsis can potentially cause septic shock. As sepsis worsens, the functions of various organs (heart, kidneys, liver, brain, lungs, etc.) deteriorate, and if the condition becomes even more severe, it leads to a state of shock.

[0006] Sepsis is understood to result from complex interactions between the causative pathogen and the host's immune, inflammatory, and coagulation systems, and both the degree of the host's response and the characteristics of the causative pathogen have a significant impact on the prognosis of sepsis.

[0007] To date, no fundamental cure for sepsis has been identified. Sepsis does not respond well to conventional anti-inflammatory treatments; even Drotrecogin alpha, the only FDA-approved drug, has had its research halted because its therapeutic efficacy was not clearly established during clinical trials. Currently, sepsis is primarily treated with intravenous antibiotics or antifungals, with the specific medication and duration determined by the type of microorganism. Additionally, hemodialysis or blood transfusions may be administered depending on the patient's condition. While sepsis can be completely cured if antibiotics and antifungals are effective, treatment becomes difficult and can lead to death in cases involving drug-resistant microorganisms, immunocompromised patients, or when treatment is initiated too late. Furthermore, the mortality rate for sepsis is very high, reaching 50–70%, and it is known to account for a significant proportion of causes of death worldwide. If complications arise from sepsis, sequelae may occur. If meningitis is present as a complication, neurological sequelae may result, while the co-occurrence of suppurative arthritis can lead to abnormalities in bone growth.

[0008] Furthermore, the biggest challenge in sepsis treatment is the cytokine storm that occurs during the progression of sepsis, which has been studied as a therapeutic target. However, to date, there are very few antibodies or drugs that effectively block the cytokine storm.

[0009] Therefore, there is a continuously growing need for safer and more effective new therapeutic agents for the prevention or treatment of sepsis. Recently, the development of sepsis treatments using novel pharmacological substances based on natural products, synthetic compounds, peptides, or proteins has been actively pursued, and among these, there is high interest in substances capable of fundamentally exhibiting therapeutic effects by acting to suppress cytokine storms. Prior art literature

[0010] Korean Registered Patent No. 10-1494031 The problem to be solved

[0011] Accordingly, the inventors have completed the present invention by diligently researching to develop a safe and effective sepsis treatment substance and by identifying that N-dodecyl-4-hydroxybenzamide of the present invention has an excellent effect in suppressing cytokine storm when treated in a sepsis model and can be usefully utilized in the treatment of sepsis through its efficacy in excellently suppressing the activity of various immune cells involved in cytokine overexpression.

[0012] Accordingly, one objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of sepsis.

[0013] In addition, another objective of the present invention is to provide a food composition for the prevention or improvement of sepsis.

[0014] In addition, another objective of the present invention is to provide a veterinary composition for the prevention or treatment of sepsis.

[0015] In addition, another objective of the present invention is to provide a feed composition for the prevention or improvement of sepsis.

[0016] In addition, another objective of the present invention is to provide a medium composition for inhibiting the activity of macrophages and B cells. means of solving the problem

[0018] The terms used in this specification are for illustrative purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0019] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0021] The present invention will be described in more detail below.

[0023] According to one aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of sepsis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:

[0024] [Chemical Formula 1]

[0025] .

[0026] The compound represented by the above chemical formula 1 of the present invention is a compound having the IUPAC name N-dodecyl-4-hydroxybenzamide (CAS Number 146501-46-4).

[0027] Although research on the specific pharmacological activity of the above compound is still ongoing, it has not been determined whether it has a direct preventive or therapeutic effect against sepsis. In the present invention, as a new use for N-dodecyl-4-hydroxybenzamide, a compound represented by Chemical Formula 1, it was first identified that it has an excellent therapeutic effect through the inhibition of cytokine storm and immune cell activation in mice with sepsis and septic shock.

[0028] The compound of Formula 1 contained as an active ingredient in the pharmaceutical composition of the present invention may exist in the form of a pharmaceutically acceptable salt.

[0029] The term "pharmaceuticalally acceptable salt" in this invention refers to any organic or inorganic addition salt of said compound at a concentration having a relatively non-toxic and harmless active effect on the patient, wherein the side effects caused by said salt do not impair the beneficial efficacy of said compound.

[0030] Acid addition salts are prepared by conventional methods, for example, by dissolving a compound in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile. An equal molar amount of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water may be heated, and then the mixture may be dried by evaporation or the precipitated salt may be filtered by suction.

[0031] At this time, organic acids and inorganic acids may be used as free acids. Inorganic acids may include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc., and organic acids may include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, hydroiodic acid, etc., but are not limited to these.

[0032] In addition, pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal salts or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium, or calcium salts as the metal salts, but is not limited to these. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

[0033] Pharmaceutically acceptable salts of the compounds of the present invention comprise salts of acidic or basic groups that may be present in said compounds, unless otherwise indicated. For example, pharmaceutically acceptable salts may include sodium, calcium, and potassium salts of hydroxyl groups, and other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrosulfate, phosphate, hydrophosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and may be prepared through methods for preparing salts known in the art.

[0034] In addition, the above compound comprises, without limitation, solvates such as its pharmaceutically acceptable salts as well as possible hydrates that can be prepared therefrom. Solvents of the above compound may be prepared using methods known in the art.

[0035] Furthermore, the above-mentioned compound may be prepared in a crystalline or amorphous form, and if prepared in a crystalline form, it may be optionally hydrated or solvated. The present invention may include not only stoichiometric hydrates of the above-mentioned compound but also compounds containing varying amounts of water. The solvates of the above-mentioned compound according to the present invention include both stoichiometric solvates and non-stoichiometric solvates.

[0036] Meanwhile, the method of obtaining N-dodecyl-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof used in the pharmaceutical composition of the present invention is not particularly limited, and may be chemically synthesized by a method known in the art or commercially available materials may be used.

[0037] The term "sepsis" in this invention refers to a condition in which systemic symptoms such as high fever, joint pain, headache, and malaise, accompanied by chills, appear due to microorganisms or toxins produced by microorganisms, such as Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Staphylococcus, and Pneumococcus, when a person is infected. If these symptoms worsen, hypotension may occur, urine output may decrease, and septic shock may develop. Although the infection route of microorganisms is not always clearly understood, appendicitis, otitis media, cutaneous suppuration, bedsores, lung disease, cholecystitis, pyelonephritis, and osteomyelitis are known causative sites of sepsis. Currently, there is no known treatment method that can fundamentally suppress or delay the onset of sepsis while alleviating its symptoms.

[0038] For example, the pharmaceutical composition of the present invention inhibits the expression of one or more selected from the group consisting of TNF-α (Tumor Necrosis Factor-alpha), IL-1β (Interleukin 1 beta), IL-6 (Interleukin 6), IFN-γ (interferon gamma) and iNOS (inducible nitric oxide synthase), thereby not only inhibiting the occurrence and / or exacerbation of a cytokine storm that causes sepsis and / or septic shock, but also inhibiting the activity of related immune cells.

[0039] The above phenomena are major factors involved in the progression of sepsis, and since the pharmaceutical composition of the present invention can effectively suppress these phenomena, it can exert the effect of preventing sepsis, delaying its onset, and alleviating the symptoms caused by it.

[0040] In a specific embodiment of the present invention, it was confirmed that when N-dodecyl-4-hydroxybenzamide (LSW04), a compound of Formula 1 of the present invention, was treated in a sepsis model, it excellently inhibited the expression of related cytokines compared to the control group (N-dodecyl-2-hydroxybenzamide (LSW03)).

[0041] This indicates that a composition comprising the compound of Formula 1 of the present invention, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof can exhibit excellent effects for the prevention or treatment of sepsis.

[0042] The term "prevention" in this invention refers to any act of suppressing or delaying the occurrence, spread, and recurrence of sepsis by administering the pharmaceutical composition of this invention, and the term "treatment" refers to any act of improving or beneficially altering the symptoms of the said disease by administering the pharmaceutical composition of this invention.

[0043] In a specific embodiment of the present invention, the treatment may mean, but is not limited to, a reduction or alleviation of signs of sepsis, a reduction in the severity of the disease, a delay or slowing of the disease, a temporary palliation or stabilization of the disease state, and other beneficial results.

[0044] The term "individual" in this invention refers to an individual suspected of having or having developed sepsis, or capable of developing sepsis, and includes all animals including humans, monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs; the said disease can be effectively prevented or treated by administering the pharmaceutical composition of this invention to these individuals. Furthermore, the pharmaceutical composition of this invention may exhibit a synergistic effect when administered in conjunction with existing therapeutic agents.

[0045] The term "administration" in this invention means providing a specific substance to a patient by any appropriate method, and the route of administration of the composition of this invention may be administered through any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, locally, intranasally, intrapulmonaryly, or rectally, but is not limited thereto. Additionally, the pharmaceutical composition of this invention may be administered by any device capable of delivering the active substance to target cells. Preferred modes of administration and formulations include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip infusions, etc. Injectable preparations can be manufactured using aqueous solvents such as physiological saline solution and Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin), etc., and may include pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).

[0046] For example, the composition of the present invention may further include a pharmaceutically acceptable carrier, diluent, or excipient, and may be formulated and used in various forms according to conventional methods for each intended use, such as oral formulations like powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, and injectable formulations like sterile injectable solutions, and may be administered orally or through various routes including intravenous, intraperitoneal, subcutaneous, rectal, and local administration. Examples of suitable carriers, excipients, or diluents that may be included in such compositions include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, the composition of the present invention may further include fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, etc.

[0047] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are formulated by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., into the above composition. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used.

[0048] Examples of oral liquid formulations include suspensions, liquid formulations, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included.

[0049] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cocoa oil, laurin oil, glycerogelatin, etc., may be used. Meanwhile, injectable preparations may contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.

[0050] The above formulation may be prepared by conventional mixing, granulation, or coating methods and may contain an active ingredient in the range of about 0.1 to 75 weight%, preferably about 1 to 50 weight%. A unit formulation for a mammal weighing about 50 to 70 kg contains about 10 to 200 mg of the active ingredient.

[0051] At this time, the composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" in the present invention refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects. The effective dose level may be determined based on factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above-mentioned factors into consideration, and this can be easily determined by a person skilled in the art.

[0052] For example, since the dosage may be increased or decreased depending on the route of administration, severity of the disease, gender, body weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0053] The preferred dosage of the compound of the present invention varies depending on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, it is preferable to administer the compound of the present invention at a dose of 0.0001 to 100 mg / kg (body weight) per day, preferably 0.001 to 100 mg / kg (body weight). Administration may be administered once a day or in divided doses via oral or parenteral routes.

[0054] The composition for the prevention or treatment of sepsis of the present invention may be prepared into a pharmaceutical formulation using methods well known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to mammals. In preparing the formulation, the active ingredient may be mixed or diluted with a carrier, or encapsulated within a carrier in the form of a container.

[0056] In addition, according to another aspect of the present invention, the present invention provides a food composition for the prevention or improvement of sepsis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.

[0057] The "improvement" of the present invention refers to any act of improving or benefiting the suspected symptoms of the target disease and the subject of the invention by using a composition comprising the compound of Formula 1 or a food-grade acceptable salt thereof.

[0058] In addition, the above-mentioned "food-grade acceptable salt" can be defined identically to the aforementioned pharmaceutically acceptable salt.

[0059] The above food composition includes compositions for all forms of food, such as health functional food, nutritional supplement, food additives, special medicinal food, and dietary supplement.

[0060] In the present invention, a health functional food refers to a group of foods to which added value has been imparted by using physical, biochemical, or biotechnological methods to make the functions of the food act or manifest for a specific purpose, or a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition.

[0061] The health functional food of the present invention includes forms such as tablets, capsules, pills, or liquids, and there are no particular limitations on the types of said health functional food. Examples may be any one selected from the group consisting of drinks, dairy products, confectionery, seasonings, beverages, snacks, candies, ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars, chocolate products, processed foods, grain products, pasta, soups, sauces and dressings, confectionery products, oils and fat products, dairy drinks, milk drinks, soy milk, soy dairy-like products, frozen foods, cooked foods, alternative foods, meat products, cheese, yogurt, bread, rolls, yeast products, cakes, cookies, and crackers, but are not limited thereto, and include all health foods in the conventional sense.

[0062] In the present invention, the food composition can be prepared by methods commonly used in the art, and the composition can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the food composition can also be prepared without limitation as long as it is a formulation recognized as a food composition.

[0063] Foods according to the present invention include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. In addition, foods include, but are not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.), and food additives. The above foods, beverages, or food additives may be manufactured by conventional manufacturing methods.

[0064] When the composition of the present invention is used as an additive to a health functional food, the composition may be added as is or used together with other health functional food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to the purpose of use. Generally, when manufacturing food or beverages, the composition of the present invention may be added to the raw material in an amount preferably 50 parts by weight or less, more preferably 25 parts by weight or less. However, in the case of long-term consumption for the purpose of health control and hygiene, the above amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount greater than the above range.

[0065] In addition to containing the active ingredients of the present invention, the food or health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional food compositions. Examples of the above-mentioned natural carbohydrates are monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; and polysaccharides, such as conventional sugars like dextrin, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The above-mentioned flavoring agents may advantageously include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).

[0066] In addition, the food composition may contain, in addition to the active ingredients of the present invention, various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages.

[0067] Since the active ingredient of the present invention can exhibit improvement effects related to inflammation or immunity through cytokine inhibition, it can be usefully utilized, for example, as a health functional food for the elderly or as a health functional food for promoting growth in the growing population. At the same time, it can be used as a special medicinal food for patients suffering from immunity or inflammation.

[0068] At this time, the above active ingredient may be used in the food composition of the present invention in an amount of 0.01 to 100 weight%. The above type of food composition may be prepared in various forms according to conventional methods known in the art. For example, as a health food, it may be prepared in the form of gum, vitamin complex, tea, juice, and drink containing the active ingredient, and the food composition having the active ingredient as an active ingredient may be consumed by granulating, encapsulating, or powdering it. The functional food composition of the present invention may include ingredients that are typically added during food manufacturing, and may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings.

[0069] For example, when manufactured as a drink, in addition to the active ingredients of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, jujube extract, licorice extract, etc. may be additionally included.

[0070] The above food composition may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, it may contain extracts for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination.

[0071] In the case of long-term consumption for the purpose of health and hygiene or health control, the food composition of the present invention can be taken for a long period of time because there are no problems in terms of safety.

[0073] In addition, according to another aspect of the present invention, the present invention provides a veterinary composition for the prevention or treatment of sepsis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.

[0074] The veterinary composition according to the present invention may be administered according to a number of administration methods widely known in the art and may be adjusted to suit the treatment of each of these animals. These compositions may be in the form of a solution, or a suspension for oral administration or injection, or in a solid or semi-solid form, or in the form of a powder, capsule, granule, sugar-coated tablet, soft capsule, spray, caplet, pill, tablet, or paste. Depending on the formulation and drug, the veterinary composition may further include conventional pharmaceutical ingredients for preparing liquid or solid formulations to be administered orally or parenterally. In addition, in the case of formulations for oral administration, these formulations may be administered directly to animals and may be mixed into food, but are not limited thereto.

[0076] In addition, according to another aspect of the present invention, the present invention may provide a feed composition for preventing or improving sepsis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.

[0077] The above active ingredient can be prepared in the same way as in the case of the above pharmaceutical composition or food composition.

[0078] The feed composition of the present invention may be a feed additive or a compound feed.

[0079] The active ingredient of the present invention can exhibit an overall improvement effect due to the enhancement of the cytokine inflammatory immune environment, and therefore can be included in a feed composition as a growth promoter for animals or livestock.

[0080] Specifically, the feed containing the active ingredient according to the present invention can be manufactured in various forms of feed known in the art, and preferably may include concentrated feed, roughage, or special feed.

[0081] Concentrated feeds include seed grains such as wheat, oats, and corn; bran, which is a byproduct obtained by refining grains and includes rice bran, wheat bran, and barley bran; oilseed meal, which is a byproduct obtained by extracting oil from soybeans, rapeseed, sesame, flaxseed, and coconut; residues such as residual starch, which is the main component of starch residue remaining after removing starch from sweet potatoes and potatoes; fish meal, fish residue; fish soluble, which is a concentrated fresh liquid obtained from fish; meat meal, blood meal, feather meal; skim milk powder; dried whey, which is the residue obtained when making cheese from milk and casein from skim milk; and animal feeds such as yeast, Chlorella, and seaweed.

[0082] Forage includes fresh fodder such as wild grass, pasture grass, and green cuts; root vegetables such as feed turnips, feed beets, and a type of turnip called lutebarger; silage, which is a stored feed made by filling a silo with fresh grass, green cut crops, and grains and fermenting them with lactic acid; hay made by cutting and drying wild grass and pasture grass; straw of livestock crops; and leaves of legumes.

[0083] Special feeds include mineral feeds such as shells and rock salt, urea feeds such as urea or its derivatives such as diuretic isobutane, feed additives and dietary supplements, which are substances added in small amounts to compound feed to supplement components that are prone to being lacking when only natural feed ingredients are mixed, or to improve the shelf life of the feed.

[0084] The feed composition according to the present invention may include various feed additives.

[0085] In the present invention, the term "feed additive" refers to a substance added to feed for the purpose of various effects, such as supplementing nutrients and preventing weight loss, improving the digestibility and utilization of fiber in the feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress during the summer. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act and may additionally include mineral preparations such as sodium bicarbonate (baking soda), bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamin preparations such as carotene, vitamin E, vitamins A, D, E, nicotinic acid, and vitamin B complex; protected amino acid preparations such as methionine and lysic acid; protected fatty acid preparations such as calcium salts of fatty acids; probiotics (lactic acid bacteria preparations); probiotics such as yeast cultures and mold fermentation products; and yeast preparations.

[0086] The feed composition according to the present invention is not particularly limited and can be applied to any individual intended to promote the improvement of overall immune inflammation. The individual refers to animals, for example, non-primates (e.g., cattle, pigs, horses, cats, dogs, rats, and mice) and mammals including primates (e.g., monkeys, e.g., cynomolgous monkeys and chimpanzees). The individual is a livestock animal (e.g., horses, cattle, pigs, etc.) or a pet animal (e.g., dogs or cats).

[0087] The dosage of the feed composition according to the present invention will depend on a number of factors such as the animal's species, size, weight, and age. In principle, a typical dosage may be in the range of 0.001 to 10 g per animal / day, but is not limited thereto.

[0089] In addition, according to another aspect of the present invention, the present invention provides a medium composition for inhibiting the activity of macrophages and B cells, comprising as an active ingredient a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.

[0090] Since the composition of the present invention includes the above-described N-dodecyl-4-hydroxybenzamide (LSW04) as an active ingredient, the common details between the two are omitted to avoid excessive complexity in this specification. Effects of the invention

[0092] Since the composition of the present invention has an excellent cytokine storm suppression effect in sepsis and septic shock, it can be usefully used as an active ingredient in compositions for the prevention or treatment of such conditions. Brief explanation of the drawing

[0094] Figure 1 shows the results of drug analysis of LSW03 (control group) and LSW04 (experimental group) in animals with CLP-induced sepsis. Figure 2 shows the timeline of LSW04 drug administration in animals with CLP-induced sepsis. Figure 3 shows the results of measuring serum cytokines at the beginning (5 h) in an animal model of CLP-induced sepsis with the drug LSW04. Figure 4 shows the results of measuring serum cytokines in the late (24 h) period in an animal model of CLP-induced sepsis with the drug LSW04. Figure 5 shows the results of immune cell analysis by the LSW drug in the pericerty (PerC) and spleen 24 hours after CLP induction. Figure 6 shows the results of the analysis of immunogene expression by the drug LSW04 in liver tissue 24 hours after CLP induction. Figure 7 shows the timeline of LSW04 drug administration in an animal model of LPS-induced sepsis. Figure 8 shows the measurement results of serum cytokines by the drug LSW04 in an animal model of LPS-induced sepsis. Figure 9 shows the results of immune cell analysis by the LSW drug in an LPS-induced sepsis animal model. Specific details for implementing the invention

[0095] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0097] Preparation Example 1: Preparation of Administration Drug

[0098] N-dodecyl-4-hydroxybenzamide (hereinafter LSW04), the drug to be administered, and N-dodecyl-2-hydroxybenzamide (hereinafter LSW03), the control, were synthesized by the convergent conformation method by Molecules & Materials (Room E3-303, Industry-Academic Cooperation Building, 141 Gajeong-ro, Yuseong-gu, Daejeon).

[0099] [Chemical Formula 1]

[0100]

[0101] [Chemical Formula 2]

[0102]

[0104] Preparation Example 2: CLP-induced sepsis animal model

[0105] After anesthetizing the mouse (C57BL / 6), a 1 cm incision was made in the lower abdominal cavity, and the cecum was sutured at one-third of its length. A hole was made in the middle section with a 25G needle, and the cecum was inserted into the abdominal cavity. The incision was sutured shut, and the mouse was allowed to rest.

[0107] Example 1. Candidate Drug Selection

[0108] As a preliminary experiment to confirm the effects on sepsis, the candidate drugs were administered to CLP-induced sepsis mice in the control group (LSW03) and the experimental group (LSW04). As shown in Figure 1, in the control group, there was no change in the expression levels of intraperitoneal B immune cells (CD11b / B220), young macrophages (CD11b / Gr-1), and cytokines (TNF-α, IL-6, etc.) compared to the CLP-induced group, but significant changes were observed in the experimental group.

[0109] Accordingly, the drug LSW04 was selected as the active ingredient of the present invention, and LSW04 was used in the following examples.

[0111] Example 2. Analysis of the effects of drug LSW04 on a CLP-induced sepsis animal model

[0112] To determine whether the drug LSW04 is effective against sepsis, CLP-induced sepsis mice were treated as follows and analyzed (Fig. 2):

[0113] a. LSW04 (30 mg / kg) was injected into the peritoneal cavity of mice 12 hours before CLP induction.

[0114] b. CLP (Cecum Ligation and Puncture) was induced at 0 hours, and LSW04 (30 mg / kg) was injected into the peritoneal cavity of mice a second time at 4 hours.

[0115] c. To measure initial cytokine changes, blood was collected from the tail vein at 5 hours and serum was isolated.

[0116] d. Mice were sacrificed at 24 hours for late expression cytokine, immune cell, and gene analysis.

[0118] 2-1. Cytokine Expression Analysis

[0119] As a result of analyzing the cytokines expressed early after CLP induction, as shown in Figure 3, the expression of pro-inflammatory cytokines TNF-α (850 pg / ml) and IL-6 (53 ng / ml) increased significantly in the mouse serum analysis of the CLP-induced group, but in the group administered with the LSW04 drug, the expression of TNF-α (decreased by about 3.5 times) and IL-6 (decreased by about 1.7 times) showed a very significant decrease.

[0120] In addition, as a result of analyzing late-expressed cytokines after CLP induction, as shown in Figure 4, the expression of IFN-γ (129 pg / ml) increased significantly in the mouse serum analysis of the CLP-induced group, but the expression of IFN-γ (about 5-fold decrease) showed a very significant decrease in the group administered with the LSW04 drug.

[0122] 2-2. Immunocyte Analysis

[0123] As a result of isolating and analyzing immune cells from the peritoneal cavity and spleen 24 hours after CLP induction, it was confirmed that the expression of MHC II and F4 / 80 in macrophages among the peritoneal immune cells was suppressed by the drug LSW04, as shown in Figure 5 (PerC). In addition, CD4 T cells in the spleen increased after injection of the drug LSW04, but CD8 T cells showed no change, and B cells (B220 / IgM) decreased after injection of the drug LSW04 (Spleen).

[0125] 2-3. Genetic analysis in liver cells

[0126] As a result of isolating liver tissue at 24 hours after CLP induction and analyzing the expression of immune genes, as shown in Figure 6, the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and iNOS, an enzyme related to immune response, was significantly increased in CLP-induced liver tissue, but administration of the drug LSW04 significantly suppressed the expression of these genes.

[0128] Example 3. Analysis of the effects of drug LSW04 on an LPS-induced sepsis animal model

[0129] To determine whether the drug LSW04 is effective against endotoxin-induced sepsis, septic shock was induced in LPS-induced septic mice by treatment as follows, and then analyzed (Fig. 7):

[0130] a. LSW04 (30 mg / kg) was injected into the peritoneal cavity of mice 12 and 2 hours before CLP induction.

[0131] b. LPS (10 mg / kg) was injected into the abdominal cavity at 0 hours, and blood was collected from the tail vein at 5 hours to measure initial cytokine changes and serum was isolated.

[0132] d. At 22 hours, LSW04 (30 mg / kg) was injected into the peritoneal cavity of mice for the third time, and mice were sacrificed at 24 hours for analysis of late-expressed cytokines, immune cells, and genes.

[0134] 3-1. Cytokine Expression Analysis

[0135] As a result of analyzing the cytokines initially expressed after LPS induction, as shown in Figure 8, LPS induction significantly increased the concentrations of TNF-α (720 pg / ml) and IL-6 (20 ng / ml) in the serum, and the LSW04 drug significantly decreased the concentrations of TNF-α (inhibited by about 2 times) and IL-6 (inhibited by about 2 times).

[0137] 3-2. Analysis of Celiac Immune Cells

[0138] As a result of analyzing the effect of the LSW04 drug on macrophages activated by LPS, as shown in Figure 9, it was found that the expression of immune substances MHCII, F4 / 80, and PD-1 activated by LPS (10 mg / kg) was significantly reduced by the LSW04 drug.

[0140] In summary, the LSW04 drug of the present invention suppressed the overexpression of cytokines resulting from an excessive immune response in sepsis and also excellently suppressed the activity of immune cells that cause cytokine expression. Therefore, the LSW04 drug of the present invention can be used in the treatment of sepsis as an excellent therapeutic agent capable of suppressing the cytokine storm that occurs in sepsis.

[0142] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of sepsis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 2 A pharmaceutical composition for the prevention or treatment of sepsis according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate inhibits the expression of one or more selected from the group consisting of TNF-α (Tumor Necrosis Factor-alpha), IL-1β (Interleukin 1 beta), IL-6 (Interleukin 6), IFN-γ (interferon gamma), and iNOS (inducible nitric oxide synthase). Claim 3 A pharmaceutical composition for the prevention or treatment of sepsis according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate inhibits the expression of macrophages and B cells. Claim 4 A food composition for the prevention or improvement of sepsis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 5 A veterinary composition for the prevention or treatment of sepsis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 6 A feed composition for the prevention or improvement of sepsis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 7 A medium composition for inhibiting the activity of macrophages and B cells comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] .